Surrogate endpoints poor proxy for survival in cancer drug approval process
Surrogate endpoints used to support the majority of new cancer drugs approved in the U.S. often lack formal study, according to the authors of a study published in the June issue of Mayo Clinic Proceedings. This analysis ...
May 26, 2016
0
21